ERBB2 and breast cancer: In conclusion, we reported that pathologists' use of AI analyzers to assess HER2, ER, and PR status as an important characterization of breast cancer molecular subtypes improved the agreement of pathologists across IHC stains and thus molecular subtypes of breast cancer.